# RELYVRIO - (3GM/PACKET; 1GM/PACKET ; For Suspension)

| | | | |
|---|---|---|---|
| **Generic Name** | SODIUM PHENYLBUTYRATE; TAURURSODIOL | **Innovator** | AMYLYX |
| **Dosage** | 3GM/PACKET; 1GM/PACKET ; For Suspension | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | None | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.